How Is Viatris’ Stock Performance Compared to Other Biotech Stocks?
Over the past six months, Viatris has lagged behind its biotech peers, and Wall Street analysts continue to exercise caution regarding the stock's future outlook.
5 Undervalued ETFs to Ride on Powell's Market Optimism
The Federal Reserve lifted confidence amid economic uncertainty, sparking optimism in the U.S. stock market. Chair Jerome Powell kept interest rate steady at policy meeting and maintained the Fed’s two-rate...
Tempus AI Stock Eyes Best Rally In 5 Months Amid Pelosi-Linked Hype, But Retail’s Turning Doubtful Now
A regulatory filing from Wednesday night disclosed that Tempus AI founder and CEO Eric Lefkofsky sold 946,084 shares of Tempus between Jan. 15-17.
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher.